This is what I’ve been holding out hope for TTE, with BRAVE potential. Maybe that’s what AD is banking on, too. It would be therapeutic justice for all the longs who have been dragged through the darkest depths of this journey since the first anchor selloff, pre adcom (2013), pre-Du. What an ending that would be!
"Something ludicrous like that is not only fair, but appropriate for an end to this rollercoaster ride."
I guess we can all dream. I still see little value of Vascepa regardless of a huge success with BRAVE. IPE manufacturers will do well, but how does Amarin monetize this indication when CVD has shown to be such a stinker? This company and brand have serious value issues.
Market Data 
Markets 
AI
